Sign In

Alex Pasteur

Venture Capitalist and Partner at F-Prime Capital Partners

Alex Pasteur is a Partner at F-Prime Capital based in London.2 He has been working in healthcare investing since 2001 and focuses on investments in therapeutics and healthcare IT.12

Some key points about Alex Pasteur:

Professional Experience

  • Partner at F-Prime Capital since October 20123
  • Board Observer at Castor since July 20213
  • Previously worked at MVM Life Science Partners LLP in the US and Europe from 2005 to 201212

Education

  • Ph.D. in Chemistry from the University of Cambridge123
  • M.A. in Natural Sciences from the University of Cambridge123

Investment Portfolio

Alex Pasteur's investment portfolio includes or has included companies such as:

  • Castor (Ciwit B.V.)12
  • Acacia Pharma Group (acquired by Eagle Pharmaceuticals)2
  • Adaptimmune Therapeutics (NASDAQ: ADAP)12
  • Arvelle Therapeutics (acquired by Angelini Pharma)12
  • Genomics PLC12
  • Orchard Therapeutics (NASDAQ: ORTX)12
  • Oviva AG12
  • Owkin Inc.12
  • Pulmocide Ltd.23

Additional Roles

Alex Pasteur also serves as a board member or director for several companies, including:

  • Tenpoint Therapeutics3
  • NodThera Limited3
  • Oviva3
  • Owkin3

His experience and expertise in healthcare investing, combined with his scientific background, make him a valuable asset in the biotech and healthcare investment sectors.

Related Questions

What are Alex Pasteur's main responsibilities at Castor?
How did Alex Pasteur transition from MVM Life Science Partners to F-Prime Capital?
What are some of the notable companies in Alex Pasteur's investment portfolio?
How has Alex Pasteur's background in chemistry influenced his investment strategies?
What are the key challenges Alex Pasteur has faced in healthcare investing?
Alex Pasteur
Alex Pasteur, photo 1
Alex Pasteur, photo 2
Add to my network

Experience

Partner at F-Prime Capital Partners (October 2012 - Present)
Director at Tenpoint Therapeutics (December 2020 - Present), Director at NodThera Limited (February 2018 - Present), Director at Oviva (September 2016 - Present), Director at Owkin (March 2019 - Present), Director at Arvelle Therapeutics (February 2020 - January 2021), Director at Acacia Pharma (August 2013 - March 2018), Board Observer at Genomics plc (January 2018 - Present), Board Observer at Castor (July 2021 - Present), Board Observer at Pulmocide (December 2013 - Present), Board Observer at Adaptimmune Therapeutics PLC (September 2015 - May 2016), Partner at MVM (2005 - 2012), Investment Manager at Gateway Fund (2001 - 2005)

Education

PhD in Chemistry from University of Cambridge (1992 - 1996), Master of Arts (MA) in Natural Sciences from University of Cambridge (1989 - 1992) - Specialized in Chemistry, Cell Biology

Location

London, England, United Kingdom